Amylin Expands Manufacturing Facility in Ohio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Amylin Expands Manufacturing Facility in Ohio


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Hamilton, OH (May 2)—Amylin Ohio LLC, a subsidiary of Amylin Pharmaceuticals (San Diego, CA, www.amylin.com), is expanding construction at its manufacturing facility in West Chester, Ohio. The expansion increases the company’s total investment to approximately $400 million.

The manufacturing facility is in the process of being equipped to manufacture the company’s long-acting release formulation of exenatide, which is being developed to treat Type-2 diabetes. The expanded facility is expected to create up to 500 jobs over the next three years.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here